GlassScriptPhysician profile
Charles B Murdock
NPI 1679533640
$6,714.51
in general payments reported to CMS, 2019-2025
33 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $878 · 2021: $682 · 2022: $776 · 2023: $1,191 · 2024: $1,437 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,515 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,514.86 |
| Education | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $1,302.92 | 2019-2025 | Vafseo, Auryxia |
| Vifor Pharma, INC. | $559.45 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $548.47 | 2019-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $499.93 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $468.93 | 2021-2024 | |
| Travere Therapeutics, INC. | $408.29 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $392.59 | 2020-2024 | Acthar, Terlivaz |
| Glaxosmithkline, LLC. | $384.97 | 2019-2024 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $301.12 | 2022-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $207.30 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $194.26 | 2022-2024 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $192.95 | 2019-2023 | Jynarque |
| Ardelyx, INC. | $172.46 | 2023-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $134.16 | 2019-2022 | |
| Amgen INC. | $126.51 | 2019-2024 | Krystexxa, Parsabiv, Tavneos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $126.12 | 2024-2025 | Rivfloza, Wegovy |
| Aurinia Pharma U.S., INC. | $117.52 | 2021-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $113.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.49 | 2021-2024 | Jardiance |
| Daiichi Sankyo INC. | $59.59 | 2021-2023 | Injectafer |
| Lilly USA, LLC | $56.39 | 2024-2025 | Jardiance |
| Ultragenyx Pharmaceutical INC. | $32.63 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $27.95 | 2025 | |
| Scpharmaceuticals INC. | $27.63 | 2025 | |
| Arbor Pharmaceuticals, INC. | $24.95 | 2019 | |
| Kyowa Kirin, INC. | $23.09 | 2025 | |
| Rockwell Medical, INC. | $20.79 | 2020 | |
| Lundbeck LLC | $20.76 | 2019 | |
| Seqirus USA INC | $17.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.33 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Hikma Pharmaceuticals USA | $15.93 | 2023 | Mitigare |
| Allergan, INC. | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Murdock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.